HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation.

Abstract
The ubiquitin-proteasome system is the primary proteolytic pathway implicated in skeletal muscle atrophy under catabolic conditions. Although several studies showed that proteasome inhibitors reduced proteolysis under catabolic conditions, few studies have demonstrated the ability of these inhibitors to preserve skeletal muscle mass and architecture in vivo. To explore this, we studied the effect of the proteasome inhibitor Velcade (also known as PS-341 and bortezomib) in denervated skeletal muscle in rats. Rats were given vehicle or Velcade (3 mg/kg po) daily for 7 days beginning immediately after induction of muscle atrophy by crushing the sciatic nerve. At the end of the study, the rats were euthanized and the soleus and extensor digitorum longus (EDL) muscles were harvested. In vehicle-treated rats, denervation caused a 33.5 +/- 2.8% and 16.2 +/- 2.7% decrease in the soleus and EDL muscle wet weights (% atrophy), respectively, compared to muscles from the contralateral (innervated) limb. Velcade significantly reduced denervation-induced atrophy to 17.1 +/- 3.3% in the soleus (P < 0.01), a 51.6% reduction in atrophy associated with denervation, with little effect on the EDL (9.8 +/- 3.2% atrophy). Histology showed a preservation of muscle mass and preservation of normal cellular architecture after Velcade treatment. Ubiquitin mRNA levels in denervated soleus muscle at the end of the study were significantly elevated 120 +/- 25% above sham control levels and were reduced to control levels by Velcade. In contrast, testosterone proprionate (3 mg/kg sc) did not alleviate denervation-induced skeletal muscle atrophy but did prevent castration-induced levator ani atrophy, while Velcade was without effect. These results show that proteasome inhibition attenuates denervation-induced muscle atrophy in vivo in soleus muscles. However, this mechanism may not be operative in all types of atrophy.
AuthorsBlake C Beehler, Paul G Sleph, Latifa Benmassaoud, Gary J Grover
JournalExperimental biology and medicine (Maywood, N.J.) (Exp Biol Med (Maywood)) Vol. 231 Issue 3 Pg. 335-41 (Mar 2006) ISSN: 1535-3702 [Print] England
PMID16514182 (Publication Type: Journal Article)
Chemical References
  • Boronic Acids
  • Proteasome Inhibitors
  • Pyrazines
  • RNA, Messenger
  • Ubiquitin
  • Testosterone
  • Bortezomib
  • Proteasome Endopeptidase Complex
Topics
  • Animals
  • Boronic Acids (pharmacology)
  • Bortezomib
  • Gene Expression Regulation (drug effects)
  • Male
  • Muscle Denervation
  • Muscle, Skeletal (drug effects, innervation, metabolism, pathology)
  • Muscular Atrophy (metabolism, pathology)
  • Proteasome Endopeptidase Complex (physiology)
  • Proteasome Inhibitors
  • Pyrazines (pharmacology)
  • RNA, Messenger (analysis, genetics)
  • Rats
  • Rats, Sprague-Dawley
  • Sciatic Nerve (surgery)
  • Testosterone (pharmacology)
  • Ubiquitin (analysis, genetics, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: